TGFB1 and chronic myelogenous leukemia, BCR-ABL1 positive: Consistently, the co-treatment of siSMAD5 and BMP + TGF-β1 resulted in a higher proliferation rate in CD34+ CML cells compared to that of cells exposed to BMP + TGF-β1.